Triazolam is a short-acting benzodiazepine primarily used for the treatment of severe insomnia and sleep disturbances. It exerts its pharmacological effect by enhancing the activity of gamma-aminobutyric acid (GABA) at the GABA_A receptor, leading to sedation, hypnosis, and anxiolysis.
Due to its rapid onset and short duration of action, triazolam is typically prescribed for short-term use, especially in patients with difficulty falling asleep.
Common uses include:
∙ Short-term treatment of insomnia
∙ Sedative premedication before minor surgical or diagnostic procedures
∙ Sometimes used off-label for managing acute agitation or anxiety in clinical settings
Parent: Triazolam
Impurities in triazolam may arise from its multi-step chemical synthesis, including benzodiazepine ring formation, halogenation, and triazole substitution. As a controlled substance used orally, impurity levels are regulated under USP, EP, and ICH Q3A/B guidelines.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Triazolam is prescribed for short-term treatment of insomnia, especially when patients have trouble initiating sleep. It is also used in preoperative sedation.
It enhances the effect of GABA, the brain’s main inhibitory neurotransmitter, by binding to the benzodiazepine site on the GABA_A receptor. This produces sedative, hypnotic, and anxiolytic effects.
Yes. Triazolam has a high potential for dependence and withdrawal symptoms if used beyond the recommended short-term duration.
Store in a cool, dry place, protected from light and moisture. As a Schedule IV controlled substance, it must be stored securely to prevent misuse.
